A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Key facts

Sponsor

Fate Therapeutics

Intervention

FT819(drug)

Enrollment

244 enrolled

Eligibility

12-70 years · All sexes

Timeline

2024 – 2042

Study locations (17)

• Providence Medical Foundation, Fullerton, California, United States
• University of California Irvine, Irvine, California, United States
• Children's Hospital Los Angeles Division Of Rheumatology, Los Angeles, California, United States
• University of California San Francisco, San Francisco, California, United States
• University of Minnesota Medical School, Minneapolis, Minnesota, United States
• University of Nebraska Medical Center, Omaha, Nebraska, United States
• Montefiore Medical Center, New York, New York, United States
• Duke University Health System, Durham, North Carolina, United States
• MetroHealth, Cleveland, Ohio, United States
• University of Oklahoma, Oklahoma City, Oklahoma, United States
• Jefferson Einstein Hospital Philadelphia, Philadelphia, Pennsylvania, United States
• Regional One Health, Memphis, Tennessee, United States
• Hôpital La Pitié Salpêtrière, Paris, France
• Uppsala University, Uppsala, Uppland, Sweden
• Manchester University NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
• +2 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07556484
  Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
  Mayo Clinic
• RECRUITINGEARLY PHASE1NCT07507201
  Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
  The Children's Hospital of Zhejiang University School of Medicine
• RECRUITINGNCT07258524
  PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated Vasculitis
  University of Edinburgh
• RECRUITINGPHASE1NCT07315087
  CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE2NCT07160608
  Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
  Alexion Pharmaceuticals, Inc.
• RECRUITINGPHASE3NCT06983821
  Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
  Ottawa Hospital Research Institute
• RECRUITINGPHASE3NCT07168161
  BDB-001 Phase III Trial in ANCA-Associated Vasculitis
  Staidson (Beijing) Biopharmaceuticals Co., Ltd
• RECRUITINGNCT07151521
  (68)Ga-FAPI PET/CT in Patients With ANCA-associated Vasculitis
  Ruijin Hospital

See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →